Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)

2021 ◽  
Vol 157 ◽  
pp. 71-80
Author(s):  
Arndt Stahler ◽  
Volker Heinemann ◽  
Veronika Schuster ◽  
Kathrin Heinrich ◽  
Annika Kurreck ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Molecular Subtypes

scholarly journals CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer

2019 ◽  
Vol 121 (7) ◽  
pp. 593-599 ◽  
Author(s):  
Fotios Loupakis ◽  
Paola Biason ◽  
Alessandra Anna Prete ◽  
Chiara Cremolini ◽  
Filippo Pietrantonio ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Molecular Subtypes

scholarly journals Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer

Oncotarget ◽  
2018 ◽  
Vol 9 (27) ◽  
pp. 18698-18711 ◽  
Author(s):  
Akira Okita ◽  
Shin Takahashi ◽  
Kota Ouchi ◽  
Masahiro Inoue ◽  
Mika Watanabe ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Predictive Factor ◽  
Molecular Subtypes ◽  
Chemotherapeutic Efficacy

Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3552-3552
Author(s):  
Arndt Stahler ◽  
Volker Heinemann ◽  
Veronika Schuster ◽  
Annabel Helga Sophie Alig ◽  
Laura Elisabeth Fischer ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Regression Model ◽  
Metastatic Colorectal Cancer ◽  
Cox Regression ◽  
Molecular Subtypes ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Prognostic Impact ◽  
Multinomial Regression ◽  
Multinomial Regression Model

3552 Background: Prognostic biomarkers beside RAS/BRAF status are necessary to identify metastatic colorectal cancer (mCRC) patients who benefit from combined (COMB) versus sequential (SEQ) treatment with fluoropyrimidine, bevacizumab and irinotecan (randomized phase III XELAVIRI trial). Methods: mRNA was extracted from formalin-fixed paraffin embedded (FFPE) tumor tissue of 337 patients, gene expression was measured by the Nanostring PanCancer Progression Panel. Consensus molecular subtypes (CMS) classification was re-derived using a multinomial regression model. Data of Guinney et al. (Nat. Med. 2015. 21:1350-6) and FIRE-3 served as training and validation set. RAS/BRAF MUT were assessed by pyrosequencing. Median overall (OS) and progression free survival (PFS), hazard ratios (HR) and 95% confidence interval (CI) were estimated by Kaplan-Meier method and univariate Cox regression. Results: The multinomial regression model employed in the present analysis correctly predicted CMS labels in 98.3 % of the original Guinney- and 100.0 % of FIRE-3 population. In XELAVIRI, CMS subgroups were predicted as follows: CMS1: n = 62 (18.4 %); CMS2: n = 174 (51.6 %); CMS3: n = 9 (2.7 %); CMS4: n = 92 (27.3 %). A general prognostic impact of CMS was not observed when all patients were analysed. In RAS/BRAF WT mCRC patients, substantial benefit of COMB versus SEQ treatment was shown for OS and PFS in CMS2 and CMS4, but not in CMS1. Conversely, OS was significantly longer for COMB treatment in patients with RAS MUT and CMS1 mCRC, while SEQ treatment was not inferior in RAS MUT and CMS2 or CMS4 subgroups (see TABLE). Additional data for overall response rates, early tumor shrinkage and sidedness might be presented at the meeting. Conclusions: This retrospective analysis of XELAVIRI suggests that CMS may serve as biomarker that predicts response to initially combined versus less intensive sequential chemotherapy in patients with RAS/BRAF WT mCRC.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document